US FDA reviewing pretomanid for tuberculosis

The US Food and Drug Administration is evaluating a new drug application for pretomanid, a new tuberculosis drug candidate. Pretomanid would be used in combination with bedaquiline and linezolid to treat patients with multi- or extensively drug-resistant TB. Pretomanid was developed by the TB Alliance, a global nonprofit group dedicated to advancing TB drug development.